B 형 간염 백신의 효과 - 산모의 HBeAg 양성 유무에 따라

The preventive efficacy for HBV infection and chronic HBV carrier rate by active and passive immunoprophylaxis was observed in 49 newborn infants whose mothers were healthy HBV carriers with normal ALT activity at delivery. All infants were divided into 3 groups; Group A received HBIG at birth and HB Vaccine (Hepavax- B) at month 0, 1 and 6. Group B received first or second vaccine only. Group C received no vaccine. ALT activity, HBsAg and anti-HBs were tested every 3 months for 18 rnonths after delivery, and the results were analyzed in 3 groups according to the mothers HBeAg positivity. 1) The anti-HBs response was57.1% (16/28) in Group A and 76.9% (10/13) in the control group whose mothers vere normal. The anti-HBs response was 64.3% (9.14) and 57.1% (8/14) according to the mothers HBeAg positivity and negativity. The anti-HBs response was 56.3% (9/16) in male and 66.7% (8/12) in female infants. The anti-HBs response svas higher in female infants and infants a hose mothers were normal or HBeAg positive carriers. 2) Chronic HBV carrier rate in infants of HBeAg positive mothers was 14.3% (2/l4) in Ciroup A, 72.7% (8/11 ) in Group 8, 100% (6/6) in Group c and was statistically significant (p=0.037) (c=0.816). There was no significant difference hetween group A, B, and C in infants of HBeAg negative mothers. 3) The positive rate of HBsAg showed significant difference between Groups A and B, A and C, A and (B+C), (A+B) and C in all 3 monthly follow-up tests in infants of HBeAg positive mothers. But there was no significant difference between (groups A, B, and C in infants of HBeAg negative mothers. The results suggest that the anti-HBs response was lower in infants of HBsAg carrier mothers. The preventive efficacy of vaccine for HBV infection and chronic HBV carrier rate was excellent in infants of HBeAg positive mothers but not significant in infants of HBeAg negative mothers by the active and passive immunoprophylaxis.